Table 3.
Sensitivity and specificity of selected studies and blood biomarkers for detecting hepatocellular carcinoma.15,16,21,24–29
| Sensitivity | Specificity | |
|---|---|---|
| Ultrasound15,16 | 51–87% | 80–100% |
| CT16,21 | 68–91% | 87–98% |
| MRI16,21 | 77–100% | 84–97% |
| Contrast enhanced ultrasound24 | 85% | 91% |
| AFP | 25–65% | 80–94% |
| DCP | 72.7% | 90% |
| DCP + AFP | 87% | 69% |
| GP-3 | 55.1% | 97% |
| GP-3 + AFP | 75.5% | 83.3% |
| miR-21 | 61.1% | 83.3% |
| miR-15b | 98.3% | 15.3% |
| miR-130b | 87.7% | 81.4% |
| miR-122 | 87.5% | 97–97.5% |
| miR-224 | 87.5% | 97–97.5% |
| miR-122 + AFP | 97.5% | 100% |
AFP, alpha-fetoprotein; CT, computed tomography; DCP, des-gamma-carboxyprothrombin; GP-3, glypican-3; miR, microRNAs; MRI, magnetic resonance imaging.